Lv1
28 积分 2026-02-26 加入
Bivalency of natalizumab promotes inhibition of dynamic VLA-4 adhesion beyond affinity gain
2小时前
求助中
Treatment of systemic lupus erythematosus: new therapeutic options
8天前
已完结
Immunopathogenesis and Therapeutics of Systemic Lupus Erythematosus: an Integrative Review
8天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
10天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
10天前
已完结
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review
20天前
已完结
Review Article: TL1A Inhibitors in IBD ‐ Mechanistic Rationale and Clinical Evidence
20天前
已完结
Stress–immune–Repigmentation niche in vitiligo: Mechanistic integration and therapeutic implications
1个月前
已完结
Vitiligo
1个月前
已完结
Targeted mRNA Delivery Using Bispecific Antibody-Lipid Nanoparticle Complexes
1个月前
已完结
皖公网安备34019202002308
